Shimizu, Masaki http://orcid.org/0000-0003-1077-7772
Mizuta, Mao
Okamoto, Nami
Yasumi, Takahiro
Iwata, Naomi
Umebayashi, Hiroaki
Okura, Yuka
Kinjo, Noriko
Kubota, Tomohiro
Nakagishi, Yasuo
Nishimura, Kenichi
Mohri, Mariko
Yashiro, Masato
Yasumura, Junko
Wakiguchi, Hiroyuki
Mori, Masaaki
Funding for this research was provided by:
Research on rare and intractable diseases, Health and Labour Sciences Research Grants
Article History
Received: 12 September 2019
Accepted: 6 January 2020
First Online: 10 January 2020
Ethics approval and consent to participate
: This is a retrospective study, approved by the Ethics Review Board of Osaka Medical College [No.333 (1964)], the main study center, on July 2016, after which approval was obtained from each of the 13 other participating medical centers. Guardians and patients were provided information by means of an opt-out form.
: Not applicable.
: Tokyo Medical and Dental University (TMDU) received unrestricted research grants for Department of Lifetime Clinical Immunology from AbbVie GK, Ayumi Pharmaceutical, Chugai Pharmaceutical, CSL Behring, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Ono Pharmaceutical, Towa Pharmaceutical, and UCB Japan. TMDU paid the salary of Masaaki Mori. The authors declare that they have no competing interests.